CGT Industry Upgrade Series - Binjiang Hangzhou Station Announces Guest Lineup and Files IPO Prospectus

Aug 20, 2024 11:22 CST Updated 11:22

2024中国园区行杭州KV_画板 1 副本.jpg

On July 16, the ninth stop of the CGT Industry Upgrade Series·Park Tour concluded successfully in Chengdu. In August, the tenth stop·Hangzhou Binjiang will take the baton and embark on its journey.

The 10th session will feature substantive, high-impact discussions to help the industry navigate current challenges. Focusing on key issues in the cell and gene therapy (CGT) sector—such as financing, pipeline advancement, and collaborations—we invite ecosystem partners, including innovative pharmaceutical companies, CXO and supply chain enterprises, and investment institutions, to share insights and engage in dialogue, thereby fostering connections and cooperation.

Organized by the Healthcare Innovative Ecosystem Alliance (HIEA), co-organized by Xingcheng Biotech, Yeasen Biotechnology, Lepu Biopharma, Shenyan Biotech, Legend Capital, Gaoxin Jintou Group, Jintou Shidai, BIA, and Zero Magnetic Valley (Xintiandi) Center, and undertaken by VCBeat New Medicine【No Need to Race, Go Further】CGT Industry Upgrade Series · Park Tour Stop 10 will be held at 14:00 on Thursday, August 22, in the Roadshow Hall, 2nd Floor, Block A, Beiao Building, Binjiang, Hangzhou.

Event Information

■ Stop 10: Hangzhou Binjiang, Bei'ao Building

Event Duration：Thursday, August 22, 2024, 14:00

Venue：Roadshow Hall, 2nd Floor, Tower A, Bei'ao Building, No. 768 Jianta Street, Binjiang District, Hangzhou

Organizer:Healthcare Innovative Ecosystem Alliance (HIEA)

Co-organized by:Xingcheng Biotech, Yeasen Biotechnology, Lepu Biopharma, Shenyuan Biotech, Legend Capital, Gaoxin Jintou Group, Jintou Times, BIA, Zero Magnetic Valley (Xintiandi) Center

Organizer:VBHealth

Supporting Organizations:Shanghai Pudong Development Bank, Hangzhou Branch

Bei'ao Building

# Highlights

High-net-worth attendees：Enterprise founders and department heads and above attend the conference to learn from best practices

Highly Practical Content：Guests will engage in in-depth discussions on topics including the methodology of cell and gene therapy, lessons learned from common pitfalls, service case studies, and insights into emerging trends.

Precision Engagement and Communication：Targeted invitations to guests, ensuring high-quality networking opportunities for attending enterprises

Event Agenda

■ 14:00-14:10

Moderator | Event Expectations and Ecosystem Synergy

Liu Xiao |Xingcheng Bio, Vice President of Business and Marketing

Deputy Director of the MAH Special Committee, China Pharmaceutical Enterprise Management Association

Park Leadership| ParkAddress and Future Outlook

Address by Leaders of the Zero-Magnetic Valley (Xintiandi) Center

Cai Rongrong | VCBeat Business Director

■ 14:10-15:16

CGT R&D Company Roadshow

(3 slides, 8-minute presentation + 3-minute Q&A)

Xu Kai | Founder, Norn Biotech

Zeng Xun | The First Affiliated Hospital, Zhejiang University School of Medicine

Li Zhaozhong | Co-founder and CTO of NewLink

Tang Jianbin | Professor at Zhejiang University, Founder of Messenger Biotech

Liu Jun | Founder, New Life Health Technology

Zhang Chi | Founder of Innoway

Xu Yuhong | CEO of Gaotian Bio

Kangbaiyu

■ 15:16-16:04

# Flash Presentation: Core Value of Supply Chain Enterprises

(2-slide PPT, 5-minute presentation + 3-minute Q&A)

Li Junhui | Vice President of Science, Technology and Production at Xingcheng Bio

Tan Guosheng | Yeasen Biotechnology, Director of Key Accounts

Yuan Jun | Vice President & CTO, Kangsheng Biologics

Chen Lin | Director of Business Development, Shenyan Biotech

Zhou Qiankai | Anshengda NGS Application Scientist

Jury Lineup

Wang Jin | President, Manhattan Investment (Hangzhou)

Wang Jinhao | Senior Investment Manager, Zhejiang University Innovation

Yanan Wang | Director and President, Kaitai Capital

Zheng Jiayi | Senior Investment Manager, Langyu Capital

Zhong Yangcheng | Investment Director, Dan En Capital

Legend Capital

■ 16:04-16:20 Tea Break

■ 16:20-17:00 Panel 1

How Can Party A and Party B Interact Constructively and Join Forces to Weather the Storm During Extraordinary Times?

Xu Kai | Founder, Nuoen Bio

Li Zhaozhong | Co-founder and CTO of Nurency

Li Junhui | Vice President of Science, Technology and Production at Xingcheng Bio

Tan Guosheng | Yeasen Biotechnology, Director of Key Accounts

Yuan Jun | Vice President & CTO, Kangsheng Bio

Chen Lin | Director of Business Development, Deep Research Bio

Xiao Liu | Vice President of Business and Marketing, Xingcheng Biotech (Moderator)

■ 17:00-17:40 Panel 2

How Can CGT Companies Effectively Pursue “Financing and Business Development” in the New Landscape?

Zeng Xun | The First Affiliated Hospital, Zhejiang University School of Medicine

Tang Jianbin | Professor at Zhejiang University, Founder of Messenger Biotech

Wang Jin | President, Manhattan Investment (Hangzhou)

Wang Yanan | President, Kaitai Capital

Chen Ke | General Manager, Technology Finance Department, SPDB Hangzhou Branch

Wu Chao | General Manager, VCBeat New Medicine (Moderator)

■ 18:00-20:00 Invitation-Only Dinner

Guest Introduction

Liu Xiao

Xingcheng BiotechVice President of Business and Marketing

Deputy Director of the MAH Special Committee, China Pharmaceutical Enterprise Management Association

Liu Xiao,Former Head of Marketing, Greater China, Danaher Biotechnology Group; previously held positions including Asia-Pacific Marketing Director, Greater China Marketing Director, Consumables Sales Manager, Business Development Manager, and Product Manager at companies such as Cytiva, GE Life Sciences, PerkinElmer, and Thermo Fisher Scientific.

Ph.D. in Strategy, University of Montpellier, France; EMBA, Nankai University; M.Sc. in Biology, University of Manchester; Postgraduate Studies in Finance, The University of Hong Kong; Currently pursuing an M.Sc. in Psychology at Arizona State University, USA. Industry Professor at UCMT; Honorary Director of GDA. Senior Engineer in Measurement, Testing, and Instrumentation (China). Doctoral Supervisor for Ph.D. in Health Management, DBA, and MBA programs at the University of Montpellier, France.Distinguished Lecturer for the Business School Workshop at The University of Hong Kong; Distinguished Lecturer for the Business School Workshop at Nankai University; Lecturer for the Advanced Leadership Training Program in Biopharmaceuticals at Peking University Health Science Center; Guest Lecturer at Yihong Business School. Vice Chairman of the MAH Special Committee under the China Pharmaceutical Enterprise Management Association; Chief Researcher at the Life Sciences Enterprise Research Center of E-Drug Manager; Special Researcher at the China Biomedical Infrastructure Alliance. Planner/Host of the “ChatCGT” column.

Xu Kai

Founder of Norn Biotech

Xu Kai, Founder, Chairman, and Chief Scientist of Nuoen Biotechnology. He earned his master’s degree from the Cancer Institute of Peking Union Medical College. With 25 years of experience in gene therapy technology development and clinical research at Baylor College of Medicine and The University of Texas M.D. Anderson Cancer Center in the United States, he participated in clinical trials of gene therapy drugs for lung cancer, including adenovirus p53 and liposomal TUSC2. He has been granted more than 10 invention patents in China and abroad.

Zeng Xun

The First Affiliated Hospital, Zhejiang University School of Medicine

Zeng Xun earned his Ph.D. from the Chinese Center for Disease Control and Prevention, conducted postdoctoral research and served as an Assistant Researcher in the Department of Immunology at Stanford University, and worked as a Research Fellow at the First Affiliated Hospital of Zhejiang University School of Medicine. His research focuses on cellular immunotherapy. He has published more than 30 papers as first or corresponding author and has presided over multiple projects funded by the National Natural Science Foundation of China.

Li Zhaozhong

Co-founder and CTO of NewLink

Li Zhaozhong, Co-founder and CTO of Nurengjie Biopharmaceutical Technology Co., Ltd., holds a Ph.D. from the Chinese Academy of Medical Sciences and completed his postdoctoral research at the University of Florida. He previously served as a Senior Scientist at AAVet Therapeutics and participated in establishing the Virus Center at the University of Texas Southwestern Medical Center, where he was responsible for developing AAV production processes and cGMP manufacturing. He contributed to the technology transfer of products to Taysha Gene Therapies and Neurogene, Inc. With over ten years of experience in researching AAV-mediated neurodegenerative diseases and CMC development, he has designed and led multiple GMP AAV production lines, with products already submitted for clinical trials. He formerly served as CTO at Huayi Lejian.

Tang Jianbin

Professor at Zhejiang University, Founder of Messenger Biotech

Jianbin Tang, Professor, Doctoral Supervisor, and Recipient of the National Excellent Young Scientists Fund. He received his Ph.D. in Polymer Chemistry and Physics from Zhejiang University in 2006. From 2006 to 2008, he conducted postdoctoral research at the University of Wyoming in the United States. Between 2008 and 2016, he served as a Lecturer and then Associate Professor at the College of Chemical and Biological Engineering, Zhejiang University. Since 2017, he has been a Professor at the same college. His primary research interests include biomaterials, drug delivery, and gene delivery. He has published more than 150 papers indexed by SCI, which have received over 9,000 citations. He holds more than 30 authorized invention patents. His honors include the Second Prize of the National Natural Science Award and the First Prize of the Zhejiang Provincial Natural Science Award.

Liu Jun

Founder, New Life Health Technology

Liu Jun holds a Ph.D. from the joint program between South China University of Technology and BGI Genomics, where he studied under Professor Wang Jian, founder of BGI Genomics. He has dedicated 12 years to the research and development of tumor liquid biopsy technologies and products at BGI Genomics and New Horizon Health, respectively. Dr. Liu has led or participated in more than 20 invention patents and conducted the world’s first study on the mutational background of plasma cell-free DNA, with findings published in Annals of Oncology.

Wang Jin

President, Manhattan Investment

Wang Jin, President of Manhattan Capital Investment Company (Hangzhou) and founder of the Qilin Club, graduated from the Department of Biological Sciences at Zhejiang University. He later pursued a Ph.D. in Biomedical Sciences in the United States. After graduation, he joined Roche, a major U.S. pharmaceutical company, where he held successive roles in research, technology development, and mergers, acquisitions, and investment financing. He subsequently transitioned to Wall Street, focusing on healthcare investments at Paramount Capital, a top-tier venture capital firm. Having previously served at Paramount Capital and co-founded SAPA, Wang returned to China in 2002 to establish Manhattan Capital, engaging in angel investing. His portfolio includes over ten well-known enterprises such as DXY and Youda Biotechnology.

Wang Yanan

Caitai Capital, Managing Director and President

Yanan Wang, Managing Director and President at Kaitai Capital, oversees investments in the gene and cell therapy sectors. He has invested in and managed more than ten projects, including Junsei Biologics, Huancode Biosciences, Dash Pharmaceuticals, Zhi Xin Hao Zheng, Hua Boron Neutron, and Jiayin Biologics. He holds a Master’s degree from the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, and a Bachelor’s degree from Wuhan University.

Zhong Yangcheng

Danen Capital, Investment Director

Zhong Yangcheng, Investment Director at Danen Capital, graduated from the School of Life Sciences at Fudan University. He specializes in the incubation and investment of early-stage pharmaceutical projects, including cell and gene therapies, macromolecular drugs, and targeted protein degradation. He has led investments in more than ten innovative drug projects, such as Caike Biotechnology, Zhiyu Biosciences, Xueji Biotechnology, and Weimei Genetics.

Li Junhui

Xingcheng Bio, Vice President of Science and Technology Production

Li Junhui, Ph.D. in Biochemical Engineering, graduated from East China University of Science and Technology. He holds an MBA from Antai College of Economics and Management, Shanghai Jiao Tong University. With nearly 20 years of experience in the R&D and industrialization of biopharmaceuticals, he has served as Production Director at Shanghai ICT Co., Ltd., and as Manager and Director at Shanghai RAAS Blood Products Co., Ltd., where he was responsible for R&D, regulatory affairs, and quality management. He is well-versed in the manufacturing processes and quality control of plasmids, lentiviruses, and CAR-T cells. He possesses extensive expertise in process development for mammalian cell platforms, as well as upstream process development and GMP manufacturing of viral vectors. Multiple projects under his leadership have received IND approval. He has rich experience in team management.

Tan Guosheng

Yeasen Biotechnology, Director of Key Accounts

Tan Guosheng, a graduate of Nanjing University, has many years of experience in sales and marketing of pharmaceuticals and biological raw materials. He currently serves as the Key Account Director at Yeasen Biotechnology, focusing on driving cooperation with key accounts (KA). He is involved in the company’s product layout and market strategy formulation for the Cell and Gene Therapy (CGT) sector and possesses in-depth knowledge of the upstream and downstream CGT industry chain.

Zou Yang

LePure Biotech, Vice President of R&D Center

Zou Yang studied at the School of Life Sciences, University of Science and Technology of China, where he earned his Bachelor’s, Master’s, and Ph.D. degrees in Molecular Biology. He has previously held positions at GE Healthcare and Sartorius. With extensive experience in the biopharmaceutical industry, he participated in and led key R&D projects involving single-use films for biopharmaceutical applications, single-use bioreactors, and virus removal filtration membranes.

Chen Lin

Shenyan Biotechnology, Director of Business Development

Chen Lin graduated from Fudan University Shanghai Medical College with a major in Biochemistry and Molecular Biology. She is primarily engaged in oncology research and has many years of experience in laboratory management and project management. She currently serves as the Director of Business Development at Shenzhen Shenyan Biotechnology Co., Ltd.

Zhou Qiankai

Anshengda NGS Application Scientist

Zhou Qiankai graduated from Soochow University and has eight years of experience in the high-throughput sequencing industry. He specializes in application development and technical support for high-throughput sequencing products, with a focus on the application of next-generation sequencing (NGS) technology in biosafety assessments for cell therapies, gene therapies, mRNA vaccines, and antibody drugs—particularly in the study of viral vector integration sites. He has extensive experience supporting Investigational New Drug (IND) applications for multiple products.

Wu Chao

General Manager, VCBeat New Medicine

Wu Chao earned his bachelor’s and master’s degrees from the School of International Pharmaceutical Business at China Pharmaceutical University. With over a decade of experience in the pharmaceutical industry, he has extensive expertise in industrial research and project collaboration. He previously held positions at the Strategy Department of China Resources Sanjiu, the China Resources Group’s Xiong’an New Area Working Group, and Xi’an Jiaotong-Liverpool University, where he engaged in strategic research, integrated industry-city development planning, commercialization of scientific achievements, and innovation ecosystem building. In 2021, he joined VCBeat and co-founded the VCBeat New Medicine media and research platform. He has established in-depth content coverage and resource accumulation in cutting-edge therapeutic areas and indications, including radiopharmaceuticals, organoids and organ-on-a-chip technologies, cell and gene therapy (CGT), and non-alcoholic steatohepatitis (NASH), thereby fostering new consensus and connections within the industry.

*The above guests are listed in agenda order, not by rank.

*Slide to view more details

Event Scale: 50 people/session

Event Registration:

Capillaries 17782369627 (WeChat ID same)

Event Collaboration:

Ms. Fu 17851017836 (WeChat ID same as phone number)

👇 Long-press to scan the QR code and add the assistant 👇

Reply “Campus Tour” to register

Company Profile

About Xingcheng Bio

CoJourney is a professional gene and cell therapy CDMO integrating plasmid, viral vector, and mRNA production, preparation, and analytical testing. It has successful experience in filing Investigational New Drug (IND) applications for plasmids and viral vectors in both China and the United States without receiving any deficiency letters. The company provides customized services including process development, cGMP manufacturing, analytical method development, and product testing and release for plasmids, viral vectors, and mRNA.

Xingcheng Company was co-founded by senior CMC experts with commercialization experience in the gene and cell therapy field, along with accomplished scientists and entrepreneurs. With dual headquarters located in Zhejiang, China, and Pennsylvania, USA, the company has established GMP manufacturing facilities for plasmids, viral vectors, and mRNA that comply with FDA, EU, and NMPA regulations. Equipped with advanced production and analytical instrumentation, our team possesses extensive process development capabilities and practical expertise. Upholding the philosophy of “Acting with Utmost Sincerity,” we leverage robust processes that exceed industry standards to provide partners with high-purity, high-yield, and cost-effective premium services for the preparation of plasmids, viral vectors, and mRNA at various production scales, from R&D to GMP grade.

About Yeasen Biotechnology

Yeasen Biotechnology (Shanghai) Co., Ltd. is a high-tech enterprise focused on core raw materials in the upstream segment of the life science industry chain, engaged in the research and development, manufacturing, and sales of biological reagents across three major categories: molecular biology, proteins, and cells. By integrating technological development pathways for molecular enzymes, proteins, antibodies, nucleic acids, and cells, Yeasen Biotechnology has become one of the few companies in China that simultaneously covers all three major categories of biological reagents, possessing both independent R&D capabilities for core technologies and large-scale production capacity.

The company develops, manufactures, and sells thousands of types of biological reagents, meeting customers’ integrated procurement needs for various categories of biological reagents. Its core product portfolio spans multiple categories, including qPCR series, NGS series, reverse transcription series, nucleic acid extraction and purification series, PCR series, molecular cloning series, in vitro transcription series, antibodies, protein purification series, protein analysis series, recombinant proteins, cell analysis series, cell culture series, cell transfection series, and reporter gene detection series. These products are widely applied in fields such as life science research, diagnostic testing, and biopharmaceuticals.。

About LePure Biotech

Shanghai Lepu Biotechnology Co., Ltd. was established in 2011 and has integrated outstanding brands such as Grise Fluid, Kangsheng Biology, and Sterilex through an inorganic growth strategy. Its business scope currently covers multiple application scenarios, including cell culture, filtration and purification, single-use systems, and industrial-grade contamination control clean solutions. The company has now become a widely recognized leading supplier providing end-to-end upstream biopharmaceutical process solutions.

Mission & Vision: Driven by technological innovation, we provide high-quality bioprocessing solutions and are committed to becoming the most trusted partner for global biopharmaceutical companies.

About Deep Research Biotech

Shenyan Biologics, established in 2014, is a core upstream supplier in the field of cell and gene therapy (CGT), providing leading technical services and manufacturing tools to CGT enterprises, including viral vector production solutions and comprehensive solutions for cell-based drug manufacturing.

In the viral vector production solutions sector, Shenyan Biology has designed and implemented its proprietary EuBioX automated laboratory system. By integrating advanced technologies such as big data analytics, bioinformatics, and automation, the company innovatively developed the EuLV® system for large-scale lentiviral vector production using stable producer cell lines. This breakthrough addresses the technical bottlenecks associated with scaling up lentiviral vector manufacturing, leveraging globally leading technology to significantly enhance production efficiency and product consistency while substantially reducing production costs.

Meanwhile, as a leading enterprise in automated cell preparation equipment in China, Shenyan Biology has independently developed the CellSep® series of cell processing systems, which are suitable for the standardized production of various cell-based therapies. The company has also launched equipment such as sterile tube welders, heat sealers, and wave bioreactors, providing an integrated automated solution for cell therapy manufacturing and comprehensively enhancing production efficiency.

Shenyan Bio possesses unique interdisciplinary advantages and has accumulated profound technical expertise in the field of Cell and Gene Therapy (CGT). Upholding its mission to “Empower CGT, Solve Industry’s Toughest Challenges,” the company will continue to expand the frontiers of therapeutic possibilities.

About Legend Capital

Legend Capital was established in April 2001 and is a leading fund management firm in China specializing in early-stage venture capital and growth-stage private equity. Over its more than two decades of development, Legend Capital has adhered to international standards, creating best practices in fund operations and management. Through a proactive value-added service system, Legend Capital fosters innovative corporate growth, consistently delivering strong investment returns across multiple sectors while driving industrial advancement and social progress in China. With the vision of becoming an investment firm with global influence, Legend Capital upholds the core value of “Wealth with Integrity” and actively fulfills its social responsibilities.

Legend Capital maintains a deep focus on investments in the healthcare sector, systematically building its portfolio across the broader health industry. In this field, it has invested in leading companies in various sub-sectors that are listed on both the A-share and Hong Kong stock markets, including Pharmaron (300759.SZ) (03759.HK), WuXi AppTec (603259.SH) (02359.HK), WuXi Biologics (02269.HK), Innovent Biologics (01801.HK), New Horizon Health (06606.HK), and Mingde Biology (002932.SZ).

About Gaoxin Jintou Group

Hangzhou Gaoxin Jintou Holding Group Co., Ltd. was established in 2015 with a registered capital of RMB 1.566 billion. It is the only district-supervised enterprise in the High-Tech Zone (Binjiang) engaged in quasi-financial services. The company is positioned to empower the commercialization of scientific and technological achievements and foster the development of high-tech industries. Its business framework primarily encompasses quasi-financial services such as cooperative funds, equity investment, and financing guarantees, as well as sci-tech innovation services and the data elements industry.

The wholly-owned subsidiary, Hangzhou Gaoxin Financing Guarantee Co., Ltd., was established in 2000 and primarily engages in policy-based financing guarantee services for small and micro enterprises;

Hangzhou Hehe Venture Capital Co., Ltd., established in 2021, is the first state-owned private equity fund management company in the High-Tech Zone (Binjiang), primarily engaged in equity investment business;

Hangzhou Gaoxin Digital Commerce Group Co., Ltd., established in 2023, primarily engages in the authorized operation of public data and the investment and construction of data infrastructure.

About Jintou Times

Hangzhou Jintou Shidai Enterprise Management Co., Ltd. (hereinafter referred to as “Jintou Shidai”) is a joint venture established by Hangzhou Gaoxin Jintou Holding Group Co., Ltd. and Hangzhou Shidai High-Tech Industrial Park Co., Ltd. By leveraging the flexibility of market-oriented mechanisms, it organically integrates government planning, state-owned construction, and market operations to achieve a synergistic effect where “1+1+1>3.” The company is committed to transforming Bei’ao Building into a hallmark of the biopharmaceutical industry in the High-Tech Zone (Binjiang), a nexus for entrepreneurs, a talent hub, and a fertile ground for investment and financing.

About BIA

Hangzhou High-Tech Industrial Development Zone (Binjiang) Biopharmaceutical Innovation Alliance (BIA) is an open, non-profit collaborative organization jointly initiated by leaders of multiple innovative pharmaceutical enterprises within the zone, targeting all innovative companies in the biopharmaceutical industry. With technological innovation as the core and service to its members as the mission, BIA leverages established experts and enterprises in the fields of innovative drugs, in vitro diagnostics, and high-end medical devices within the zone to identify promising innovative biopharmaceutical companies. By integrating research institutions, hospitals, contract research organizations (CROs), professional investment firms, and government agencies within the zone, BIA fosters a biopharmaceutical industrial ecosystem. This initiative aims to promote the development of the innovative biopharmaceutical sector in the High-Tech Zone (Binjiang) and facilitate the public listing of more biopharmaceutical companies.

About the Zero Magnetic Valley (Xintiandi) Center

Zero-Magnetic Science Valley (Smart New World), covering an area of approximately 7.6 square kilometers, is formed by the integration of the International Zero-Magnetic Science Valley and Smart New World. It serves as the primary hub for the clustered development of the life and health industry and acts as a key vehicle for the High-Tech Zone (Binjiang) to create its “second breakthrough point” following the digital economy, thereby rebuilding a trillion-yuan industrial cluster. The area encompasses “One Valley and One Town,” namely the International Zero-Magnetic Science Valley and the Binjiang Digital Health Town. The International Zero-Magnetic Science Valley centers on ultra-high-sensitivity ultra-weak magnetic field and inertial measurement devices, along with five interdisciplinary research platforms, focusing primarily on three industries: zero-magnetic medicine, quantum information, and artificial intelligence. The Binjiang Digital Health Town focuses on internet healthcare, medical big data, and medical AI, accelerating the deep integration of “BT + IT + AI” and prioritizing the development of a “1+2” industrial model characterized by smart healthcare at its core, complemented by high-end medical devices and innovative drugs. Through the coordinated development of the “Valley” and the “Town,” the area strives to build a “new center for green development, a new highland for digital health, and a new model for future cities.”

About Shanghai Pudong Development Bank Hangzhou Branch

SPD Bank’s Hangzhou Branch has designated technology finance as its “No. 1 Priority Project.” Its technology finance services cover the entire lifecycle of enterprises, from start-up to maturity, offering a range of financial products—including “Pu Tou Dai,” “Pu Xin Dai,” and “Pu Chuang Dai”—to meet the financing needs of technology companies at different stages.

As of the end of 2023, SPDB’s Hangzhou Branch had served more than 4,500 technology-based enterprises, with an outstanding balance of technology-related loans exceeding RMB 50 billion, demonstrating its significant achievements in sci-tech finance and its positive contribution to local economic development.

About VCBeat Pharma

VB Pharma is a media and research platform under VCBeat that focuses on the biopharmaceutical sector. It delivers “in-depth” and “incremental” communication value to innovators and entrepreneurs through two dimensions: content and operations. In terms of content, it features exclusive financing announcements, corporate interviews, the “Drug Developers” column, in-depth industry analyses, and sector reports. On the operations front, its branded series “VB Think Tank” focuses on practical challenges, discusses industry trends, and fosters tangible collaborations through the exchange of ideas.

Special Report Achievements: [CGT】【IPO - Financial Report Analysis】【iPSC】【Radiopharmaceuticals】【Protein Degraders】【Upstream Tools】【Synthetic Biology】【Organoids】【VB Insights Salon].

Previous Reviews

Nine Organizations Join Forces to Kick Off the CGT Industry Upgrade Park Tour at Its First Stop: “Shanghai ATLATL Innovation Center”!

Ten Organizations Join Forces to Visit the Second Stop of the CGT Industry Upgrade Park Tour: “Shanghai Xingbei · Free Trade Zone No. 1”!

Ten Organizations Join Forces to Visit the Third Stop of the CGT Industry Upgrade Park Tour: "Nanjing Bio-Medicine Valley"!

Eleven Organizations Join Forces to Visit the Fourth Stop of the CGT Industry Upgrade Park Tour: "Suzhou BioBAY"!

Eleven organizations join forces to visit the fifth stop of the CGT Industry Upgrade Park Tour: "Beijing Newborn Nest Innovation Center"!

Eleven Organizations Join Forces to Visit the Sixth Stop of the CGT Industry Upgrade Park Tour: “Beijing Yichuang Gaoke Innovation Technology Park”!

Eleven Organizations Join Forces to Visit the 7th Stop of the CGT Industry Upgrade Park Tour: “Guangzhou International Business Incubator”!

Fifteen Organizations Join Forces: Check-in at Stop 8 of the CGT Industry Upgrade Park Tour—Shenzhen Weiguang Life Science Park & Bay Gravity!

BD Heats Up, Innovation Cycle Continues: Where Are Nucleic Acid Drugs Headed? (VBEF Station – RNA Forum)

Returning to Clinical Needs, Guided by Commercial Value: How to Seize the Momentum in the Current CGT Sector? (VBEF Station - CGT Forum)

Ten Organizations Join Forces: Check-In at the 9th Stop of the CGT Industry Upgrade Park Tour—Chengdu Tianfu International Bio-town!